Signaturefd LLC purchased a new position in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,471 shares of the medical technology company’s stock, valued at approximately $228,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Truewealth LLC purchased a new position in Stryker during the fourth quarter worth about $110,000. Sawyer & Company Inc purchased a new position in Stryker during the fourth quarter worth about $125,000. Sit Investment Associates Inc. boosted its holdings in Stryker by 114.3% during the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock worth $128,000 after purchasing an additional 440 shares during the last quarter. Oak Point Wealth Management purchased a new position in Stryker during the fourth quarter worth about $145,000. Finally, San Francisco Sentry Investment Group CA boosted its holdings in Stryker by 47.8% during the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 325 shares during the last quarter. Institutional investors and hedge funds own 75.71% of the company’s stock.
Several research analysts recently weighed in on the stock. ValuEngine upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Citigroup upgraded shares of Stryker from a “sell” rating to a “neutral” rating and boosted their target price for the company from $165.77 to $166.00 in a research note on Tuesday, February 27th. Morgan Stanley boosted their target price on shares of Stryker from $179.00 to $186.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. Oppenheimer reiterated a “hold” rating and issued a $165.00 target price on shares of Stryker in a research note on Thursday, February 1st. Finally, Guggenheim reiterated a “buy” rating on shares of Stryker in a research note on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the company. Stryker currently has an average rating of “Buy” and a consensus target price of $163.85.
In related news, VP William E. Berry, Jr. sold 1,306 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $164.42, for a total transaction of $214,732.52. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Yin C. Becker sold 23,221 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $165.96, for a total transaction of $3,853,757.16. Following the sale, the vice president now directly owns 10,499 shares in the company, valued at approximately $1,742,414.04. The disclosure for this sale can be found here. Insiders have sold a total of 43,611 shares of company stock worth $7,178,719 in the last ninety days. 7.40% of the stock is currently owned by insiders.
Shares of Stryker Co. (NYSE:SYK) traded down $0.89 during mid-day trading on Wednesday, hitting $166.22. 480,362 shares of the company were exchanged, compared to its average volume of 1,368,070. The stock has a market cap of $62,500.00, a PE ratio of 34.05, a P/E/G ratio of 2.41 and a beta of 0.70. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12 month low of $129.82 and a 12 month high of $170.00.
Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.01. The company had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. Stryker’s revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.78 EPS. sell-side analysts anticipate that Stryker Co. will post 7.12 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s dividend payout ratio (DPR) is presently 38.37%.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/03/14/signaturefd-llc-invests-228000-in-stryker-co-syk.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.